Jubilant Pharmova Ltd
JUBLPHARMAJubilant Pharmova Ltd's price has outrun its earnings. −8.7% in a year against EPS −52.5% — the market is paying now for delivery later.
The sharpest disagreement: the price moved −8.7% in a year while annual EPS moved −52.5% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a downtrend (5 weeks in) while the P/E sits at the 84th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −45.1% year on year, and 250% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Jubilant Pharmova Ltd trades at ₹1,025, in a downtrend and 5 weeks into that stage. That is +6.3% against its own 200-day average. It sits at 67% of a 52-week range of ₹817 to ₹1,129. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 5 of stage 4, confirmed. At ₹1,025 it trades +6.3% versus its 200-day average and sits at 67% of its 52-week range (₹817–₹1,129).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +216% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Jubilant Pharmova Ltd trades at 42.1× P/E, at the pricey end of its own range (84th percentile). Its long-run median P/E is 16.9×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 42.1× is at the pricey end of its own range (84th percentile), against a long-run median of 16.9× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −52.5% against a −8.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +10.2%/yr price move, ~−15.9%/yr came from earnings growth and ~+26.1 pp from the multiple (expanding); over 10y, of the +7.3%/yr price move, ~−0.9%/yr came from earnings growth and ~+8.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Jubilant Pharmova Ltd was paying for profit growth of about 25.3% a year. Profit itself has compounded 0.3% a year over the past 10 years. Today the market pays 42.1× P/E, the 84th percentile of its own 11-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is far above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Jubilant Pharmova Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −23.0% latest against +1732.4% at its 12-quarter best), ROCE holding at 7.0%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +14.5% | +9.6% | +6.3% | +3.7% |
| Profit | −52.4% | — | −13.8% | +0.3% |
| EPS | −52.5% | — | −13.8% | +0.2% |
| Share price | −8.7% | +31.3% | +10.2% | +7.3% |
4-Factor Sector Score
37.6/100 — rank 17 of 24 in Pharma - API & CRAMS · 93% evidence confidence
Jubilant Pharmova Ltd scores 37.6 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 17. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 11.8 + 6.8 + 13.9 + 5.1 = 37.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Jubilant Pharmova Ltd reported ₹2,229 Cr of revenue in the Jun 26 quarter, +17.3% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 3.7% a year. The last full year, FY26, came in at ₹8,280 Cr. The last four reported quarters add to ₹8,607 Cr.
FY26 revenue came in at ₹8,280 Cr (+14.5% on the year), capping 10 years at 3.7% compound. The latest quarter (Jun 26) printed ₹2,229 Cr, +17.3% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +16.2% growth against the decade's 3.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +16.2% over the last 4 quarters against +12.1%/yr over the last 8 — accelerating; TTM profit −23.0% vs −20.0%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Jubilant Pharmova Ltd's operating margin is 11.0% in the Jun 26 quarter, −4.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 11.0% to 26.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.0%, −4.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 11.0%–26.0%.
🚨 Why the margin moved: operating margin went −4.1 pp year on year while gross margin went −1.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Jubilant Pharmova Ltd earned ₹56.0 Cr of net profit in the Jun 26 quarter, −45.1% year on year. Full-year FY26 profit was ₹398 Cr. The 10-year compound rate is 0.3%. That is 2.5% of the quarter's revenue. The same quarter a year earlier earned ₹102 Cr. 1 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹56.0 Cr, −45.1% year on year. On the full year, FY26 printed ₹398 Cr (−52.4%), and the 10-year compound rate is 0.3%.
🚨 Why profit moved: revenue contributed +17.3% and the margin −4.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −23.3% vs revenue +16.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 250% of Jubilant Pharmova Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹1,227 Cr of operating cash against ₹398 Cr of profit. After ₹2,640 Cr of capital spending, ₹−1,413 Cr was left as free cash.
FY26: operating cash of ₹1,227 Cr against reported profit of ₹398 Cr, leaving free cash of ₹−1,413 Cr after ₹2,640 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 250% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 250%: the cash cycle tightened 147 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 4.6× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Jubilant Pharmova Ltd's cash conversion cycle runs 47 days in FY26, down from 194 days in FY21. Capital spending ran ₹5,452 Cr over the last 3 years. At FY26 sales of ₹8,280 Cr each day of that cycle holds about ₹22.7 Cr, so roughly ₹1,066 Cr sits inside the business at any moment.
FY26: debtors at 47 days, inventory at 170 days — roughly 5.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 47 days, tighter than FY21's 194.
The full loop: cash goes out to suppliers and production on day 0; stock waits 170 days to sell; customers pay about 47 days after that; and suppliers themselves are paid at 170 days — netting out to the 47-day cycle.
In money terms: at FY26 sales of ₹8,280 Cr, each day of the cycle holds about ₹22.7 Cr — so the 47-day loop keeps roughly ₹1,066 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹5,452 Cr over the last 3 fiscal years against ₹1,191 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹4,040 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Jubilant Pharmova Ltd earns a ROCE of 9% in FY26. That is up from a trough of 3% in FY23. Return on invested capital clears the cost of that capital by −6.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.8% net margin on 0.54× asset turns.
FY26 ROCE is 9%, recovered from a FY23 trough of 3% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 4.8% net margin × 0.54× asset turns × 2.15× balance-sheet leverage ≈ 5.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 5.1% − 12.0% = a −6.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Jubilant Pharmova Ltd carries total debt of ₹3,615 Cr against shareholder equity of ₹7,096 Cr as of Mar 26, a debt-to-equity of 0.51. On the annual view that ratio went from 0.60 in FY22 to 0.51 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹3,615 Cr against shareholder equity of ₹7,096 Cr — a debt-to-equity of 0.51. On the annual view, debt-to-equity went from 0.60 (FY22) to 0.51 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 8.3 points of Jubilant Pharmova Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 12.4% of the company. Foreign institutions moved −3.6 points over the same window, to 15.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +8.3 points over 8 quarters to 12.4%; Foreign institutions: −3.6 points over 8 quarters to 15.9%; Promoters: −3.0 points over 8 quarters to 47.7%.
Why the register moved: rotation — foreign institutions −3.6 points against domestic institutions +8.3 points over 8 quarters, with promoters −3.0 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Jubilant Pharmova Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Neuland Laboratories LtdNEULANDLAB | 81.2/100Sector-leading setup100% evidence | LEADER | 33.6/35 Revenue 78.3% · PAT 100% · OPM change 23 pp 100% evidence | 19.9/25 ROCE 26.5% · OPM 35% 100% evidence | 12.0/20 P/E 60.7× · PEG 1.05 100% evidence | 15.7/20 RS sector 7.5% · RS bench 44.6% · 1Y 62.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 33.6 + 19.9 + 12 + 15.7 = 81.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Acutaas Chemicals LtdACUTAAS | 77.3/100Favorable setup76% evidence | 31.9/35 Revenue 41% · PAT 100% · OPM change 9 pp 95% evidence | 20.1/25 ROCE 31.6% · OPM 34% 76% evidence | 9.3/20 P/E 71.7× · PEG — 50% evidence | 16.0/20 RS sector 86.5% · RS bench 43.7% · 1Y 129.5%5 of 8 weeks ahead 70% evidence | |
| Exact sum: 31.9 + 20.1 + 9.3 + 16 = 77.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3IOL Chemicals & Pharmaceuticals LtdIOLCP | 73.0/100Favorable setup100% evidence | LEADER | 28.5/35 Revenue 18.5% · PAT 60% · OPM change 3 pp 100% evidence | 12.5/25 ROCE 11.3% · OPM 14% 100% evidence | 13.8/20 P/E 32.3× · PEG 0.66 100% evidence | 18.2/20 RS sector 37.2% · RS bench 81.2% · 1Y 100.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 12.5 + 13.8 + 18.2 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Laurus Labs LtdLAURUSLABS | 71.2/100Favorable setup93% evidence | LEADER | 32.2/35 Revenue 22.6% · PAT 100% · OPM change 8 pp 100% evidence | 18.2/25 ROCE 17.8% · OPM 32% 100% evidence | 5.3/20 P/E 97.3× · PEG 3.33 65% evidence | 15.5/20 RS sector 22.2% · RS bench 63.4% · 1Y 123.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 18.2 + 5.3 + 15.5 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Gland Pharma LtdGLAND | 69.7/100Favorable setup100% evidence | LEADER | 26.4/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 27% 100% evidence | 14.2/20 P/E 42.1× · PEG 1.45 100% evidence | 15.2/20 RS sector 8.2% · RS bench 45.5% · 1Y 54.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.9 + 14.2 + 15.2 = 69.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Divis Laboratories LtdDIVISLAB | 65.4/100Favorable setup100% evidence | LEADER | 26.5/35 Revenue 16.4% · PAT 26.8% · OPM change 11 pp 100% evidence | 19.1/25 ROCE 22% · OPM 41% 100% evidence | 3.5/20 P/E 83.1× · PEG 3.45 100% evidence | 16.3/20 RS sector 3.2% · RS bench 39.9% · 1Y 55.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 19.1 + 3.5 + 16.3 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Shilpa Medicare LtdSHILPAMED | 63.1/100Mixed-positive evidence100% evidence | LEADER | 27.6/35 Revenue 28% · PAT 100% · OPM change 1 pp 100% evidence | 10.3/25 ROCE 10.9% · OPM 29% 100% evidence | 5.6/20 P/E 66.1× · PEG 6.86 100% evidence | 19.6/20 RS sector 60.8% · RS bench 111.5% · 1Y 127.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.6 + 10.3 + 5.6 + 19.6 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sai Life Sciences LtdSAILIFE | 62.9/100Mixed-positive evidence93% evidence | LEADER | 27.2/35 Revenue 17.6% · PAT 48% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.6% · OPM 27% 100% evidence | 4.9/20 P/E 91.6× · PEG 3.46 65% evidence | 14.2/20 RS sector 12.7% · RS bench 51.7% · 1Y 84.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 16.6 + 4.9 + 14.2 = 62.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 9Granules India LtdGRANULES | 62.4/100Mixed-positive evidence100% evidence | LEADER | 26.4/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.8/25 ROCE 15.5% · OPM 23% 100% evidence | 10.4/20 P/E 34.7× · PEG 1.27 100% evidence | 9.8/20 RS sector 1.7% · RS bench 37.1% · 1Y 77.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 15.8 + 10.4 + 9.8 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Windlas Biotech LtdWINDLAS | 53.5/100Mixed-positive evidence77% evidence | BREAKING OUT | 16.7/35 Revenue 18.8% · PAT 9.8% · OPM change -2 pp 83% evidence | 14.5/25 ROCE 15.9% · OPM 11% 95% evidence | 11.5/20 P/E 35.1× · PEG — 50% evidence | 10.8/20 RS sector -1.8% · RS bench 34.7% · 1Y 13.7%5 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.5 + 11.5 + 10.8 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Anthem Biosciences LtdANTHEM | 53.0/100Mixed-positive evidence77% evidence | BREAKING OUT | 12.7/35 Revenue -2.1% · PAT 14.1% · OPM change 1 pp 100% evidence | 22.0/25 ROCE 30.4% · OPM 36% 100% evidence | 9.2/20 P/E 89.3× · PEG — 15% evidence | 9.1/20 RS sector -4.6% · RS bench 29.4% · 1Y 13.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 22 + 9.2 + 9.1 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12SMS Pharmaceuticals LtdSMSPHARMA | 48.7/100Mixed-negative evidence100% evidence | TURNING | 19.1/35 Revenue 10.2% · PAT 41.7% · OPM change 0 pp 100% evidence | 11.3/25 ROCE 13.3% · OPM 20% 100% evidence | 10.3/20 P/E 42.4× · PEG 1.53 100% evidence | 8.0/20 RS sector -2.8% · RS bench 32.7% · 1Y 96.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 11.3 + 10.3 + 8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Morepen Laboratories LtdMOREPENLAB | 48.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.3/35 Revenue 9.5% · PAT 51.6% · OPM change 8 pp 100% evidence | 8.5/25 ROCE 8.1% · OPM 14% 100% evidence | 9.7/20 P/E 54× · PEG 1.68 100% evidence | 10.0/20 RS sector -16.2% · RS bench 130.1% · 1Y 134.8%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.5 + 9.7 + 10 = 48.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Blue Jet Healthcare LtdBLUEJET | 46.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 5.8/35 Revenue -27.5% · PAT -34.6% · OPM change -1 pp 100% evidence | 21.0/25 ROCE 26.1% · OPM 33% 100% evidence | 13.8/20 P/E 45.8× · PEG 1.39 100% evidence | 5.9/20 RS sector -39.2% · RS bench 12% · 1Y -23.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 5.8 + 21 + 13.8 + 5.9 = 46.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Supriya Lifescience LtdSUPRIYA | 45.3/100Mixed-negative evidence100% evidence | FADING | 16.1/35 Revenue 28.2% · PAT 11.2% · OPM change -11 pp 100% evidence | 17.1/25 ROCE 25.2% · OPM 25% 100% evidence | 6.9/20 P/E 36.5× · PEG 3.11 100% evidence | 5.2/20 RS sector -11.2% · RS bench 20.4% · 1Y 38.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 17.1 + 6.9 + 5.2 = 45.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Concord Biotech LtdCONCORDBIO | 37.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 9.2/35 Revenue -6.7% · PAT -23.3% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 17.1% · OPM 32% 100% evidence | 6.7/20 P/E 56.7× · PEG 5.67 100% evidence | 7.0/20 RS sector -23.6% · RS bench 16.4% · 1Y -9.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.2 + 14.9 + 6.7 + 7 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Jubilant Pharmova Ltdthis pageJUBLPHARMA | 37.6/100Mixed-negative evidence93% evidence | TURNING | 11.8/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 6.8/25 ROCE 9% · OPM 11% 100% evidence | 13.9/20 P/E 42.1× · PEG 1.17 65% evidence | 5.1/20 RS sector -23% · RS bench 5.6% · 1Y -4.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.8 + 13.9 + 5.1 = 37.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Piramal Pharma LtdPPLPHARMA | 35.2/100Mixed-negative evidence71% evidence | LEADER | 13.0/35 Revenue 0.8% · PAT -80% · OPM change 3 pp 74% evidence | 1.4/25 ROCE 2.5% · OPM 9% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.8/20 RS sector -10.9% · RS bench 21.1% · 1Y 5.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 1.4 + 10 + 10.8 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Solara Active Pharma Sciences LtdSOLARA | 34.7/100Adverse evidence83% evidence | TURNING | 7.9/35 Revenue 15.6% · PAT -80% · OPM change -2 pp 100% evidence | 3.8/25 ROCE 4.9% · OPM 16% 100% evidence | 8.5/20 P/E 843× · PEG — 15% evidence | 14.5/20 RS sector 1.9% · RS bench 38.7% · 1Y 12.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 3.8 + 8.5 + 14.5 = 34.7 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Hikal LtdHIKAL | 33.0/100Adverse evidence81% evidence | BREAKING OUT | 11.6/35 Revenue -5.4% · PAT -80% · OPM change 2.6 pp 74% evidence | 4.3/25 ROCE 3.5% · OPM 9.2% 100% evidence | 7.4/20 P/E 65.4× · PEG — 50% evidence | 9.7/20 RS sector -21.7% · RS bench 6.9% · 1Y -14.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 4.3 + 7.4 + 9.7 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21OneSource Specialty Pharma LtdONESOURCE | 27.5/100Adverse evidence71% evidence | BASING | 11.3/35 Revenue 4.3% · PAT -80% · OPM change 0 pp 74% evidence | 3.3/25 ROCE 0.6% · OPM 27% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -27.3% · RS bench -0.8% · 1Y -15%3 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 3.3 + 10 + 2.9 = 27.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Syngene International LtdSYNGENE | 23.6/100Adverse evidence100% evidence | BASING | 6.7/35 Revenue -3.4% · PAT -56.4% · OPM change -11.3 pp 100% evidence | 8.6/25 ROCE 10% · OPM 12.3% 100% evidence | 8.1/20 P/E 52.2× · PEG 7.87 100% evidence | 0.2/20 RS sector -44.2% · RS bench -22.8% · 1Y -41%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.7 + 8.6 + 8.1 + 0.2 = 23.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Dishman Carbogen Amcis LtdDCAL | 22.1/100Adverse evidence87% evidence | ASLEEP | 7.0/35 Revenue 0.2% · PAT -80% · OPM change -11 pp 100% evidence | 4.8/25 ROCE 3.1% · OPM 9% 100% evidence | 6.4/20 P/E 145× · PEG 2.65 65% evidence | 3.9/20 RS sector -31% · RS bench -18.6% · 1Y -39.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7 + 4.8 + 6.4 + 3.9 = 22.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Cohance Lifesciences LtdCOHANCE | 20.6/100Adverse evidence82% evidence | BREAKING OUT | 3.0/35 Revenue -19.8% · PAT -80% · OPM change -19.7 pp 95% evidence | 6.8/25 ROCE 5.8% · OPM 0.3% 76% evidence | 5.5/20 P/E 156× · PEG — 50% evidence | 5.3/20 RS sector -33.4% · RS bench -9.2% · 1Y -52.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 6.8 + 5.5 + 5.3 = 20.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Jubilant Pharmova Ltd's share price today?
Jubilant Pharmova Ltd trades at ₹1,025, −8.7% over the past year. The company is valued at ₹16,331 Cr. The stock sits at 67% of its 52-week range of ₹817–₹1,129, +6.3% versus its 200-day average. On the tape, the price is in a downtrend, 5 weeks in. — as of 11 September 2026.
What were Jubilant Pharmova Ltd's latest quarterly results?
Jubilant Pharmova Ltd reported revenue of ₹2,229 Cr and net profit of ₹56.0 Cr for the Jun 26 quarter. Revenue rose 17.3% and profit fell 45.1% year on year. Earnings per share were ₹3.55. The operating margin was 11.0%, 4.0 pp lower than a year earlier. — as of 11 September 2026.
What is Jubilant Pharmova Ltd's revenue?
Jubilant Pharmova Ltd reported revenue of ₹2,229 Cr in the Jun 26 quarter, +17.3% year on year. For the full FY26 fiscal year, revenue was ₹8,280 Cr (+14.5%). Over the last 10 years revenue compounded at 3.7% a year. — as of 11 September 2026.
What is Jubilant Pharmova Ltd's profit?
Jubilant Pharmova Ltd earned ₹56.0 Cr of net profit in the Jun 26 quarter, −45.1% year on year. Full-year FY26 profit was ₹398 Cr. The operating margin ran 11.0% in the latest quarter. — as of 11 September 2026.
What is Jubilant Pharmova Ltd's market cap?
Jubilant Pharmova Ltd's market capitalisation is ₹16,331 Cr at a share price of ₹1,025. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Jubilant Pharmova Ltd's P/E ratio?
Jubilant Pharmova Ltd trades at a P/E of 42.1×, at the 84th percentile of its own 11-year range, against a long-run median of 16.9×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Jubilant Pharmova Ltd pay a dividend?
Yes — Jubilant Pharmova Ltd's dividend payout was 20% of profit in FY26, and it recorded a payout in 11 of its last 13 reported fiscal years. 2 of those years show a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Jubilant Pharmova Ltd overvalued?
On its own history, Jubilant Pharmova Ltd looks expensive: its P/E of 42.1× sits at the 84th percentile of its 11-year range (long-run median 16.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Jubilant Pharmova Ltd growing?
Not right now — Jubilant Pharmova Ltd's latest numbers are shrinking: latest-quarter revenue +17.3% year on year, profit −45.1%, and the margin −4.0 pp at 11.0%. The 10-year compound rates are 3.7% (revenue) and 0.3% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Jubilant Pharmova Ltd performing?
Jubilant Pharmova Ltd is in a downtrend, 5 weeks in. Its latest quarter's revenue rose 17.3% and profit fell 45.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Jubilant Pharmova Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −23.0% latest against +1732.4% at its 12-quarter best), ROCE holding at 7.0%. The read comes from the last 12 quarters of growth (revenue growth +16.2% latest, profit growth −23.0% latest, eps growth −23.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Jubilant Pharmova Ltd in an uptrend?
No — the price is in a downtrend (week 5 of stage 4), trading +6.3% versus its 200-day average and at 67% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Jubilant Pharmova Ltd beating the market?
On recent form, yes — Jubilant Pharmova Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +216% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Jubilant Pharmova Ltd's share price go up?
This page publishes no price forecast for Jubilant Pharmova Ltd. What it measures instead: the share price is ₹1,025, the price is in a downtrend 5 weeks in. Its P/E of 42.1× sits at the 84th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Jubilant Pharmova Ltd?
Promoters hold 47.7% of Jubilant Pharmova Ltd, foreign institutions 15.9%, domestic institutions 12.4% and the public 23.5% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 8.3 points over 8 quarters. — as of 11 September 2026.
Does Jubilant Pharmova Ltd have too much debt?
It is moderate — Jubilant Pharmova Ltd's debt-to-equity is 0.51, and operating profit covers the interest bill 6×. FY26 borrowings were ₹3,615 Cr against equity of ₹7,093 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Jubilant Pharmova Ltd's capex?
Jubilant Pharmova Ltd spent ₹5,452 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹2,640 Cr, with ₹4,040 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Jubilant Pharmova Ltd's cash flow?
Jubilant Pharmova Ltd generated ₹1,227 Cr of operating cash flow in FY26 and ₹−1,413 Cr of free cash flow after ₹2,640 Cr of capital spending. Reported profit that year was ₹398 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Jubilant Pharmova Ltd's profit real cash?
Yes — over the last 3 fiscal years, 250% of Jubilant Pharmova Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹1,227 Cr against reported profit of ₹398 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Jubilant Pharmova Ltd in its business cycle?
Jubilant Pharmova Ltd's FY26 operating margin was 15.0%, against a 13-year band of 11.0%–26.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Jubilant Pharmova Ltd's price assume?
At its price on 13 June 2026, Jubilant Pharmova Ltd was priced for profit growth of about 25.3% a year. Profit itself has compounded 0.3% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Jubilant Pharmova Ltd story?
The sharpest disagreement: the price moved −8.7% in a year while annual EPS moved −52.5% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Jubilant Pharmova Ltd a stock worth studying right now?
This is not investment advice. The machine read: Jubilant Pharmova Ltd's price has outrun its earnings. −8.7% in a year against EPS −52.5% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!